Cipla had earlier received final USFDA approval in May 2024 to market its generic Lanreotide injection in multiple strengths.

Shares of Cipla declined 4% on January 7 after the US Food and Drug Administration (FDA) disclosed inspection observations ...

Cipla clarified that its supply partner Pharmathen received nine USFDA Form 483 observations during a November 2025 ...

The Food and Drug Administration (FDA) has approved Somatuline Depot (lanreotide; Ipsen Biopharmaceuticals) injection for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in ...

The Food and Drug Administration has given Cipla its stamp of approval for lanreotide injection. The medication is the generic of Ipsen’s Somatuline Depot. It is indicated for the treatment of ...

Cipla has received the Food and Drug Administration’s blessing for lanreotide injection 120 mg/0.5 ml, 90 mg/0.3 ml, 60 mg/0.2 ml, which is the generic of somatuline depot (lanreotide) injection.

BASKING RIDGE, N.J.--(BUSINESS WIRE)--Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that the U.S. Food and Drug Administration (FDA) has approved a ...

Please provide your email address to receive an email when new articles are posted on . In the LOCKCYST I clinical trial, a low dose of Somatuline Depot injection for the treatment of polycystic liver ...

The Food and Drug Administration has approved Somatuline Depot (lanreotide) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic ...

PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) published today new data from seven abstracts to be presented at the hybrid-setting 19 th Annual European Neuroendocrine ...

MISSISSAUGA, ON, Jan. 7, 2020 /CNW/ - Ipsen Biopharmaceuticals Canada Inc. today announced the availability of a new delivery system for Somatuline ® Autogel ® (lanreotide injection) 60, 90, and 120 ...

BASKING RIDGE, N.J.--(BUSINESS WIRE)--Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that the U.S. Food and Drug Administration (FDA) has approved a ...